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Abstract
Background: Neuroendocrine tumors (NETs) are rare especially in the gallbladder. They have not been elucidated
in the pathogenesis, clinicopathological characteristics, and treatment options.
Case presentation: We present a 76-year-old woman with a gallbladder tumor and hepatic hilar lymph node
swelling. The lymph node biopsy demonstrated neuroendocrine carcinoma (NEC). We performed cholecystectomy,
hepatic hilar lymphadenectomy, extrahepatic biliary duct resection, and hepaticojejunostomy prior to
chemotherapy. Pathological examination revealed the gallbladder mass was an adenocarcinoma invading to the
muscular layer without any NEC components, whereas the hepatic hilar lymph nodes were filled with high-grade
NEC cells with negligible area of adenocarcinoma. The patient received general chemotherapy consisting of
carboplatin and etoposide, but a recurrence in the para-aortic lymph nodes occurred 4 months after surgery.
Conclusions: We report a rare case of NEC of the hepatic hilar lymph nodes that were concomitant with an
adenocarcinoma of the gallbladder. High-grade NEC generally has an aggressive behavior and an optimal
treatment strategy should be chosen for each patient.
Keywords: Neuroendocrine carcinoma, Neuroendocrine tumor, Gallbladder cancer, Intestinal metaplasia
Background
Neuroendocrine tumors (NETs) are a heterogeneous
group of tumors arising from diverse sites, with the ma-
jority occurring in the gastrointestinal tract and the
bronchopulmonary system. Gallbladder NETs are par-
ticularly rare, accounting for only 0.34% of all NETs and
less than 1% of all tumor types arising in the gallbladder
[1, 2]. In the 2010 World Health Organization (WHO)
classification of tumors of the digestive tract, NET is
classified into NET G1, NET G2, and neuroendocrine
carcinoma (NEC) based on mitotic count and Ki-67
index [3]. Here, we report a rare case of NEC in the hep-
atic hilar lymph nodes concomitant with a gallbladder
adenocarcinoma.
Case presentation
A 76-year-old woman presented to our hospital with com-
plaints of epigastralgia since a day prior to admission. La-
boratory data on admission revealed an elevation of
aminotransferase, alanine aminotransferase, ɤ-guanosine
triphosphate, and alkaline phosphatase. Serum total biliru-
bin and tumor markers, carcinoembryonic antigen (CEA),
carbohydrate antigen 19-9 (CA19-9), SPan-1, and neuron-
specific enolase (NSE), were all within normal ranges. Ab-
dominal computed tomography (CT) and magnetic reson-
ance cholangiopancreatography (MRCP) showed a mass
in an enlarged gallbladder and bulky hepatic lymph nodes
surrounding the hepatic hilum (Fig. 1a, b). There were also
no apparent lesions in upper and lower gastrointestinal en-
doscopy. Endoscopic ultrasound-guided fine-needle aspir-
ation (EUS-FNA) was performed to obtain tissue from the
hilar lymph node. Immunohistochemical staining of the
specimen identified diffuse positivity for keratin, CD56, and
synaptophysin in the tumor cells, which is consistent with
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NEC. An endoscopic naso-gallbladder drainage (ENGBD)
catheter was placed, and the bile cytology revealed class V
malignant cells. Therefore, positron emission tomography/
computed tomography (PET/CT) examination was per-
formed to evaluate other primary or metastatic lesions.
It revealed that no other accumulated lesions were identi-
fied, and the accumulation of 18F fluorodeoxyglucose
(FDG) was in the gallbladder (SUVmax 7.8) and lymph
nodes (SUVmax 13.4) (Fig. 1c, d). On the basis of these
findings, the most likely diagnosis was a gallbladder NEC
that was confined to the regional hepatic hilar lymph
nodes metastasis.
Finally, we decided to perform surgical resection prior
to chemotherapy because of concerns about complications
developing from mechanical obstruction of the hepatic
hilum by the enlarged lymph node. She underwent chole-
cystectomy, hepatic hilar lymphadenectomy, extrahepatic
biliary duct resection, and hepaticojejunostomy. The bulky
lymph nodes were totally resected as “en bloc”. There were
no apparent residual lesions surgically. The postoperative
course was uneventful and she was discharged on the
tenth day after surgery.
Macroscopically, the tumor was 58 × 42 mm in size and
was located in the fundus, which contained a yellowish
gallstone (Fig. 2a). A portion of the hepatic hilar lymph
nodes (71 × 37 mm) was also excised separately (Fig. 2b).
Microscopic examination of the gallbladder revealed a mod-
erate to well differentiated tubular adenocarcinoma infiltrat-
ing from the mucosa to the muscular layer, but not the
serosal surface, without any NEC components (Fig. 2c, d).
The tumor cells in the gallbladder are slightly positive for
synaptophysin and CD56, but negative for chromogranin A
(Fig. 2e–g). The resection margin from the liver bed was
negative for tumor cells. The epithelium around the carcin-
oma showed intestinal metaplasia with the goblet cells
(Fig. 4a), which area was stained by alcian blue (Fig. 4b).
On the other hand, the hepatic hilar lymph nodes were
composed of small round tumor cells with hyperchromatic
nuclei and scant cytoplasm (Fig. 3a). Some of the tumor
cells were large and had vesicular nuclei. The tumor cells
were arranged in sheets, cords, or in a trabecular or rosette
fashion and were interspersed with focal necrosis. They
were immunohistochemically positive for CD56, synapto-
physin, and chromogranin A (Fig. 3b–3d). The mitotic
count was 24 per 10 high-power microscopic fields, and
the Ki-67 proliferation index was 70–80%, consistent with
NEC. The surgical dissection margin of the hepatic
lymph nodes was microscopically cauterized within the
tumor cells. There was no invasion to the extrahepatic
biliary duct.
As the result of thorough pathological re-evaluation by
total segmentation, a negligible area of adenocarcinoma
was detected in the lymph nodes (Fig. 3e, f ). The adeno-
carcinoma component and the intestinal metaplastic epi-
thelium in the gallbladder were both positive for CDX2
(Fig. 4a), but the neuroendocrine component in hilar
lymph nodes was negative for CDX2 (Fig. 4b).
Postoperatively, the patient received three cycles of car-
boplatin (area under the curve of 5 on day 1 repeated every
21 days) and etoposide (80 mg/m2 on days 1 through 3 re-
peated every 21 days). During the first course, grade 4 neu-
tropenia occurred and it was managed with prophylactic
fluoroquinolones. After 4 months, multiple recurrences in
the para-aortic lymph nodes were detected, which was
pathologically demonstrated via EUS-FNA to be NEC. The
patient underwent second-line chemotherapy with amrubi-
cin (24 mg/m2 on days 1 through 3 repeated every 21 days).
Grade 4 neutropenia and anemia developed during the
courses, and she needed to receive pegylated granulo-
cyte colony-stimulating factor and red blood cell trans-
fusion. However, she died of progressive disease 8 months
after surgery.
Discussion
We present a rare case of a gallbladder cancer with regional
bulky lymph nodes composed histologically of NEC, which
was different from the histology of the primary gallbladder
adenocarcinoma. The neuroendocrine cells in the regional
lymph nodes are reasonably concluded to originate from
the gallbladder, taking into account the preoperative PET/
Fig. 1 Preoperative imaging studies. Magnetic resonance
cholangiopancreatography (MRCP) (a) and contrast-enhanced
abdominal computed tomography (CT) scan (b) show a mass
in a gallbladder with bulky hepatic lymph nodes surrounding
the hepatic hilum. c, d Positron emission tomography/computed
tomography (PET/CT) shows abnormal FDG uptake in the gallbladder
(SUVmax 7.8) and the lymph node (SUVmax 13.4). No other metastases
were identified
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CT findings as well as the postoperative pathological result
that hilar lymph nodes contained a small amount of adeno-
carcinoma cells.
According to the 2010 WHO classification, mixed adeno-
neuroendocrine carcinoma (MANEC) is defined as a tumor
where both components exceed 30% of the neoplasm [3].
The clinicopathological features of biliary MANECs include
the adenocarcinoma component being predominantly lo-
cated at the surface of the tumor and areas with the major-
ity of the invasive cells, such as lymph node metastases,
often involving neuroendocrine components [4]. Therefore,
our case does not fulfill the criteria for MANEC because of
the tiny area of adenocarcinoma, and moreover, there have
been no previous reports of this kind of pathological
feature.
On the other hand, the exact histogenetic origin of gall-
bladder NETs remains uncertain because normal gallbladder
mucosa does not contain neuroendocrine cells [5]. However,
several hypotheses have been proposed [6, 7]. Chronic in-
flammation mostly due to cholelithiasis and subsequent in-
testinal metaplasia of the gallbladder has been assumed to
be a precursor of gallbladder epithelial tumors [8, 9], and
this theory, called the metaplasia–dysplasia–carcinoma cas-
cade [10], is also suggested to be associated with neuroendo-
crine tumors [11–15]. CDX2, a homeobox gene, is involved
in the differentiation and maintenance of enteric epithelium
Fig. 2 Macro and microscopic findings of the gallbladder. Gallbladder tumor with stone (a) and hepatic hilar lymph nodes (b). The tumor consists of
well to moderately differentiated tubular adenocarcinoma (hematoxylin and eosin (H&E) stain, c ×200 and d ×400). The tumor cells in the gallbladder
are slightly positive for e synaptophysin (×400) and f CD56 (×400), but negative for g chromogranin A (×400)
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[16] and is known to be a useful immunohistochemical
marker of intestinal metaplasia of the gallbladder [17].
Acosta et al. reported a case of gallbladder MANEC that
was positive for CDX2 in both tumor components and con-
cluded that the finding supported the metaplasia–dyspla-
sia–carcinoma sequence [18]. In the present case which is
non-matching as MANEC, the adenocarcinoma compo-
nent of the primary tumor and the intestinal metaplasia le-
sions were positive for CDX2 but the neuroendocrine cells
were not (Fig. 4c, d). Therefore, these findings may indicate
that some mechanism other than a metaplastic change may
have been involved in the oncogenesis of NEC in this case.
Further analysis of oncogenic mutation may prove the rela-
tionship between gallbladder and lymph nodes. Since the
neuroendocrine cells existed only in the hilar lymph nodes,
which contained a small amount of adenocarcinoma, it
may be plausible that the neuroendocrine cells in the lymph
nodes arose from aberrant transformation of adenocarcin-
oma cells with slight neuroendocrine differentiation from
the gallbladder as similar theories have been advocated by
other authors [6, 19].
In the NCCN guidelines for resectable poorly differenti-
ated or small cell tumors, surgical resection and chemo-
therapy with or without radiotherapy are advised, although
definitive chemotherapy can be considered [20]. A recent
study showed that patients with a Ki-67 index <55% were
less responsive to platinum-based chemotherapy but had a
longer survival than patients with higher Ki-67 indexes, and
the authors concluded that patients with advanced gastro-
intestinal NEC with a Ki-67 index above 55% should be
considered for chemotherapy without delay [21]. However,
Fig. 3 Microscopic findings of a hepatic hilar lymph node. a A sheet
of differentiated small to large neuroendocrine carcinoma cells fills
up the lymph node (hematoxylin and eosin (H&E) stain, ×400). The
tumor cells in the lymph nodes are positive for b synaptophysin (×400),
c chromogranin A (×400), and d CD56 (×400). The component of
adenocarcinoma H&E stain e ×40, f ×200
Fig. 4 Staining for intestinal metaplasia. The epithelium around the tumor shows intestinal metaplasia with goblet cells (a H&E stain, ×100;
b alcian blue stain, ×100). c The adenocarcinoma component and intestinal metaplastic epithelium in the gallbladder are positive for CDX2
immunohistochemical stain (×200), d but the neuroendocrine component is negative for CDX2 (×200)
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high-grade NEC originating from the gallbladder generally
has a poor prognosis [1, 22, 23]. In our case, finally, through
the Cancer Board discussion, we selected “carboplatin and
etoposide” as first line chemotherapy. The primary treat-
ment for high-grade NEC represents on the standard regi-
mens employed for the treatment of small cell lung cancer,
which are also recommended in NCCN guideline. “Amru-
bicin” was chosen as second line, based on previous reports
[24–26]. Furthermore, since the cancer was confined to the
gallbladder and regional lymph nodes in the present case,
we proceeded to surgical resection before chemotherapy to
prevent mechanical obstructive jaundice or cholangitis
caused by bulky lymph nodes around the hepatic hilum.
However, the tumor recurred 4 months after the surgery in
spite of general chemotherapy. Most of extrapulmonary
large or small cell carcinomas are aggressive and re-
quire combined multimodality treatment, and it should
be planned for each patient based on the clinicopatho-
logical findings.
Conclusions
We report a rare case of NEC of the hepatic hilar lymph
nodes that were concomitant with an adenocarcinoma of
the gallbladder. Based on the histopathological features of
this case, some mechanism other than intestinal metapla-
sia may be involved in the oncogenesis of NEC arising
from the gallbladder. High-grade NEC generally has a
poor prognosis and planning an optimal therapeutic strat-
egy for each patient is essential.
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